文献速递湿疹皮炎与荨麻疹

阿布昔替尼24周减量治疗中重度特应性皮炎的真实世界结局:可行性与方案比较

Real-world outcomes of 24-week abrocitinib tapering in moderate-to-severe atopic dermatitis: Feasibility and regimen comparison.
PubMed 文献 · J Am Acad Dermatol · 2026-07-09

这项单中心回顾性研究纳入78例经阿布昔替尼治疗达到充分应答的中重度特应性皮炎患者,比较剂量减少与间隔延长两种24周减量方案。76例(97.4%)成功减量,第12周和第24周无复发率分别为97.4%和91.0%,平均累积剂量减少9892 mg并节省费用。

要点

  • 中重度AD患者阿布昔替尼24周减量可行,97.4%成功减量
  • 减量后第24周无复发率91.0%,平均累积剂量减少9892 mg
  • 间隔延长组策略切换率28.6%,显著高于剂量减少组8.3%

核心结论

  • 对阿布昔替尼应答良好的中重度AD患者,24周减量治疗可行,可在保持疗效的同时减轻治疗负担。

研究设计与样本

  • 单中心回顾性研究,纳入78例经阿布昔替尼治疗达到充分临床应答并接受24周减量的中重度AD患者,其中剂量减少组36例、间隔延长组42例。

主要发现

  • 76例(97.4%)成功减量,第12周和第24周无复发率分别为97.4%和91.0%。
  • 第24周平均累积剂量减少9892 mg(6908 mg vs 标准16,800 mg),节省费用¥2899.5(¥2016.7 vs 预计¥4916.2)。

关键数值与推荐

  • 减量方案包括剂量减少与间隔延长两种方式,减量期为24周。
  • 成功减量定义为完成24周减量,共76/78例(97.4%)。
  • 第12周无复发率97.4%,第24周无复发率91.0%。

临床怎么用

  • 对阿布昔替尼治疗应答良好的中重度AD患者可考虑24周减量方案以降低治疗负担和费用。
  • 选择减量方案时需注意间隔延长法因病情波动而需切换策略的比例较高。

局限性

  • 单中心回顾性设计。
  • 样本量较小。
  • 随访时间相对较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence regarding the feasibility of Janus kinase inhibitors tapering following adequate response in moderate-to-severe atopic dermatitis (AD) remains limited, and no head-to-head comparisons of tapering regimens have been conducted. OBJECTIVE: To evaluate the feasibility of 24-week abrocitinib tapering in moderate-to-severe AD patients having achieved adequate response and compare 2 tapering methods. METHODS: This retrospective study enrolled moderate-to-severe AD patients who achieved adequate clinical response with abrocitinib and underwent tapering over 24 weeks via dose reduction or interval extension. RESULTS: A total of 78 patients (36 dose reduction, 42 interval extension) were included, and successful tapering was achieved in 76 (97.4%). Nonrelapse rates were 97.4% and 91.0% at weeks 12 and 24, respectively. At week 24, mean cumulative dose was reduced by 9892 mg (6908 mg vs 16,800 mg standard), with cost savings of ¥ 2899.5 (¥ 2016.7 vs ¥ 4916.2 projected). Patients with extended dosing intervals had significantly higher strategy-switch rates due to disease fluctuation [28.6% (12/42) vs 8.3% (3/36), P = .041]. LIMITATIONS: The single-center retrospective design, small sample size, and relatively short follow-up duration. CONCLUSION: Twenty-four-week abrocitinib tapering appears feasible in well-responding moderate-to-severe AD patients, reducing treatment burden while preserving efficacy.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Deng S, He Y, Wang H, et al. Real-world outcomes of 24-week abrocitinib tapering in moderate-to-severe atopic dermatitis: Feasibility and regimen comparison. J Am Acad Dermatol. 2026. PMID: 42423580. doi:10.1016/j.jaad.2026.06.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。